Attardi E et al. Integrated genetic diagnostics of patients with early onset of de novo myelodysplastic syndromes. EHA 2022;Abstract S165.
Bernard E et al. Molecular international prognostic scoring system for myelodysplastic syndromes. N Engl J Med Evidence 2022;1(7). Abstract
Brunner AM et al. Efficacy and safety of sabatolimab in combination with hypomethylating agents in patients with very high/high-risk myelodysplastic syndrome and acute myeloid leukemia: Final analysis from a phase Ib study. ASH2021; Abstract 244.
Daver NG et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: Phase 1b results. EHA 2022;Abstract S132.
de Botton S et al. Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial. ASCO 2022;Abstract 7005.
De La Fuente A et al. Midostaurin plus intensive chemotherapy in FLT3 mutated AML. “Real life” data versus the RATIFY study. EHA 2022;Abstract P523.
DiNardo CD et al. Azacitidine and venetcolax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383(7):617-29. Abstract
El-Jawahri A et al. Psychological mobile app for patients with acute myeloid leukemia (AML): A randomized clinical trial. ASCO 2022;Abstract 12018.
Erba H et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients ages 18-75 years with newly diagnosed FLT3-ITD+ AML. EHA 2022;Abstract S100.
Hourigan CS et al. Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission. ASCO 2022;Abstract 7006.
Huang R et al. Off-the-shelf CD33 CAR-NK cell therapy for relapsed/refractory AML: First-in-human, phase I trial. EHA 2022;Abstract S133.
Jonas BA et al. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol 2022;97(8):E299-303. Abstract
Kadia TM et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2022;[Online ahead of print]. Abstract
Lachowiez CA et al. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. ASCO 2022;Abstract 7018.
Lancet JE et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-Year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2021;8(7):e481-91. Abstract
Larson RA et al. Midostaurin reduces relapsed in FLT-3 mutant acute myeloid leukemia: The Alliance CALGB 10603/RATIFY trial. Leukemia 2021;35(9):2539-51. Abstract
Lübbert M et al. 10-day decitabine vs conventional chemotherapy (‘3+7’) followed by allografting in AML patients ≥ 60 years: A randomized phase III study of the EORTC Leukemia Group, GIMEMA, CELG, and GMDS-SG. EHA 2022;Abstract S125.
Perl AE et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022;139(23):3366-75. Abstract
Pratz KW et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022;40(8):855-65. Abstract
Russell N et al. A randomised comparison of CPX-351 and FLAG-IDA in high risk acute myeloid leukaemia. Results from the NCRI AML19 trial. EHA 2022;Abstract S128.
Sallman DA et al. Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy. ASCO 2022;Abstract 7053.
Sallman DA et al. Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results. EHA 2022;Abstract S166.
Stone RM et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377(5):454-64. Abstract
Stone RM et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). ASH 2015;Abstract 6.
Uy GL et al. Transplant outcomes after CPX-351 vs 7+3 in older adults with newly diagnosed high-risk and/or secondary AML. Blood Adv 2022;[Online ahead of print]. Abstract
Voso MT et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial. Blood Adv 2020;4(19):4945-54. Abstract
Wang ES et al. Long-term results of a phase 2 trial of crenolanib combined with 7+3 chemotherapy in adults with newly diagnosed FLT3 mutant AML. ASCO 2022;Abstract 7007.
Wei AH et al. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood Cancer J 2021;11(10):163. Abstract
Yilmaz M et al. Quizartinib with decitabine and venetoclax (TRIPLET) is active in patients with FLT3-ITD mutated acute myeloid leukemia — A phase I/II study. EHA 2022;Abstract S127.